Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3234 vs placebo in NF1-related plexiform neurofibromas
CTR20260433Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tunlametinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2026; status: active.
02
Drugs
tunlametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on CTR20260433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260433.